A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.

Inclusion Criteria:

• Diagnosis of chronic (> 6 months), hepatic impairment.
• In the opinion of the Investigator, be in good health.

Exclusion Criteria:

• Severe hepatic encephalopathy.
• Prior placement of a portosystemic shunt.
• Hepatorenal or hepatopulmonary syndrome.
• Suspicion of hepatocellular carcinoma.